BB Biotech AG (BBAGF) Comparison with companies in other sectors?

BB Biotech AG has a share price of 76.79M. You can analyze BB Biotech AG (BBAGF) competitors across different market sectors through stock heatmaps.

What are BBAGF's NET and operating margins?

BB Biotech AG (BBAGF) operating margin is around 0.06, and net profit margin is approximately 0.82 as of the latest reports.

In what way does BBAGF's earnings per share (EPS) trend reflect its financial momentum?

BB Biotech AG (BBAGF) EPS is -17.29 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for BB Biotech AG is -2.19, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for BB Biotech AG?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for BB Biotech AG like P/E which is 13.25, P/B which is 0.75, and PEG which is -0.36. Compare them with sector averages to evaluate if the stock is priced fairly.

BB Biotech AG

BBAGF•PNK

Financial Services

Asset Management

$37.79

$-10.01(-20.94%)

Fundamental Analysis of BB Biotech AG (BBAGF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-17.29

P/E Ratio

-2.19

ROE

0.05%

Net Margin

0.82%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$2.90B

Shares OutstandingTotal number of shares issued

$76.79M

Book Value/ShareNet worth per share

$40.32

Revenue/ShareAnnual revenue per share

$2.76

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-17.292

Net MarginNet income as percentage of revenue

82.008%

Operating MarginOperating income as percentage of revenue

6.37%

ROEReturn on shareholders' equity

5.33%

ROAReturn on total assets

5.002%

ROCEReturn on capital employed

0.39%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.64

Cash/ShareCash and equivalents per share

$0.04

FCF YieldFree cash flow as percentage of market cap

6.34%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BBAGFFinancial Ratios Analysis details for BBAGF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BBAGFSector Benchmarking details for BBAGF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for BB Biotech AG Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of BB Biotech AG. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account BB Biotech AG's unique business strengths and challenges.

Key Financial Metrics for BB Biotech AG

For BB Biotech AG, essential financial indicators include EPS -17.29, PE -2.19, and ROE 0.05. These key ratios reveal insights into BB Biotech AG's profitability, valuation, and operational health. Understanding these metrics enables you to compare BB Biotech AG with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of BB Biotech AG

Metrics like Net Margin 82.008% and ROA 5.002% shed light on how well BB Biotech AG is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether BB Biotech AG can sustain its operations and continue growing in the future.

Valuation and Market Position of BB Biotech AG

Using ratios such as P/B Ratio 0.75 and PEG Ratio -0.36, investors can assess whether BB Biotech AG is appropriately valued based on its financials and growth potential. These figures, combined with BB Biotech AG's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for BB Biotech AG

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $2.64, provide a snapshot of BB Biotech AG's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like BB Biotech AG, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for BB Biotech AG

Investing in BB Biotech AG based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at BB Biotech AG focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;